Call Now Open
2025 Oxford-Harrington Rare Disease Scholar Award
January 15, 2025
The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical...
Continue ReadingJuly 11, 2024
University Hospitals and Case Western Reserve University team show cerebellum is a thirst-modulating brain center Continue Reading
May 17, 2024
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership (between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio) aimed at driving cutting-edge rare disease breakthroughs, is pleased to announce that it has received a philanthropic donation of up to £650,000... Continue Reading
May 01, 2024
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading
April 16, 2024
10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic Continue Reading
April 01, 2024
Call for proposals focused on proteostasis, senescence, and other novel approaches Continue Reading
March 19, 2024
2024 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Immunology Continue Reading
February 08, 2024
Dr. Paul Tesar of Case Western Reserve University and Dr. Donald F. Weaver of University Health Network selected for their work targeting novel pathways in Alzheimer’s Continue Reading
February 06, 2024
New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading
January 03, 2024
Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading
November 30, 2023
Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading